<DOC>
	<DOCNO>NCT02724449</DOCNO>
	<brief_summary>The purpose study obtain information concern safety effective use protective barrier film patient experience severe incontinence associate dermatitis .</brief_summary>
	<brief_title>A Clinical Evaluation 3M Cavilon Advanced Barrier Film Treatment Incontinence Associated Dermatitis ( IAD )</brief_title>
	<detailed_description>This open label , non randomize prospective case series evaluate 3M Cavilon Advanced Barrier Film treatment severe incontinence associate dermatitis ( IAD ) presence absence continue fecal fecal urinary incontinence . The product apply twice week maximum duration 3 week . Subjects follow twice week healing , maximum 3 week earlier , discharge facility . During study period , frequency intensity incontinence monitor , twice week photographic documentation IAD site assessment complete .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<criteria>1 . Is subject 18 year age old ? 2 . Is subject facility provide nurse care 24h per day ? 3 . Does subject severe incontinenceassociated dermatitis eg breach denude skin ? The ideal candidate would denudement present . 4 . Is subject willing photo take skin expose incontinence permit use photos potential publication ? 5 . Is subject willing release right 3M use photo ? 6 . Has subject sign Institutional Review Boardapproved inform consent document authorize use disclosure protect health information ? At NSLIJ , subject capable consent eligible enroll . The study include participant decisional impairment would render incapable informed consent . 18 year old Subjects exclude participation study answer question yes . 1 . If female , subject pregnant breast feed give birth within 3 week precede screen visit ? 2 . Does subject know allergy acrylate cyanoacrylate ? 3 . Does subject current pressure ulcer area skin affect incontinence ? 4 . Does subject active genital herpes infection ? 5 . Does subject preexist abnormal skin disease treatment area may affect skin assessment ? 6 . Does skin area involve study require treatment concomitant medication product ? 7 . Has subject enrol investigational study within 30 day Screening Visit ? 8 . Does subject medical condition opinion investigator exclude him/her participate study ? 9 . Has subject receive antifungal powder within 24 hour prior enrollment ? 10 . Has subject receive cyanoacrylate base skin protectant affect area ( Marathon ) within 72 hour prior enrollment ? 11 . Is facility unwilling discontinue use subject Dimethicone containing wipe area investigational device apply ? 12 . Is facility unwilling discontinue use subject Chlorhexidine Gluconate wipe area investigational device apply ?</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>IAD</keyword>
	<keyword>Fecal incontinence</keyword>
</DOC>